Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study
This is an extension study to investigate long term safety and efficacy of SyB C-1101 when orally administered every 3 weeks, twice daily for 14 consecutive days to the patients who have completed 6 cycles in the study 2012002 whose purpose is to investigate tolerability of SyB C-1101 when administered orally in patients with recurrent/relapsed or refractory myelodysplastic syndrome.
Myelodysplastic Syndrome
DRUG: SyB C-1101
Adverse Events, Total number affected by any adverse events (details are presented in adverse event section), Up to 3 years
Total Efficacy in Hematologic Remission (IWG2006 Criteria), SD (stable disease): according to International Working Group 2006 response criteria for myelodysplastic syndrome, SD was defined as a failure to achieve "complete remission" or "partial remission," but no evidence of progression for \> 8 weeks., Up to 3 years|Total Efficacy in Hematologic Improvement Ratio According to IWG 2006 Criteria., NCA (not considered assessable): no evidence of HI-E (hematologic improvement-erythroid), HI-P (hematologic improvement-platelet), HI-N (hematologic improvement-neutorophil), progressive disease, or relapse., Up to 3 years|Cytogenetic Response Ratio According to IWG 2006 Criteria, NCA (not considered assessable): no cytogenetic response, Up to 3 years|Overall Survival, Survived, Up to 3 years|Changes in Clinical Laboratory Test Results, Clinically significant changes, Up to 3 years
This is an extension study to investigate long term safety and efficacy of SyB C-1101 when orally administered every 3 weeks, twice daily for 14 consecutive days to the patients who have completed 6 cycles in the study 2012002 whose purpose is to investigate tolerability of SyB C-1101 when administered orally in patients with recurrent/relapsed or refractory myelodysplastic syndrome.